Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1401 (canerpaturev) plus ipilimumab in unresectable or metastatic melanoma
jRCT1080223536Phase 2Completed
- Sponsor
- Takara Bio Inc.
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canerpaturev and ipilimumab in melanoma, sponsored by Takara Bio Inc. Started May 2017; status: completed.
02
Drugs
canerpaturevipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT1080223536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223536.